A new targeted therapy is offering an unprecedented survival benefit for patients with advanced pancreatic cancer, a disease where progress has historically been slow and survival measured in months. In a large clinical trial, patients who had already exhausted other treatments lived a median of about 13 months on daraxonrasib, compared to six to seven months on standard chemotherapy, roughly doubling their survival time.
Experts describe the results as a rare turning point. “Every five to 10 years, there’s a major shift in how we treat pancreatic cancer,” says James Farrell, MD, director of the Yale Center for Pancreatic Diseases. “This is one of those moments. The doubling of survival is huge, that’s never been achieved before.” The drug is currently under review by the Food and Drug Administration (FDA) and could be approved as early as late 2026.
Pancreatic cancer remains one of the deadliest cancers in the U.S., though it is far less common than breast, prostate, colon, or lung cancers. The lifetime risk is about 1.7%, or roughly 1 in 70 people. About 90% of pancreatic cancers are driven by mutations in a gene called KRAS, which for decades was considered “undruggable” because researchers could not find a way to block its effects with medication. Earlier drugs that target KRAS have helped only small subsets of patients, since each one blocks a specific mutation.
Daraxonrasib works differently. Instead of targeting one KRAS mutation, it blocks a broad range of them at once, meaning it could potentially help far more patients than earlier KRAS-targeted drugs. The same mutations also appear in other cancers, including lung cancer, where similar therapies have already shown benefit. While the FDA review continues, the agency has allowed limited early access through a special program, so some patients with advanced pancreatic cancer can already receive the drug.
“For patients, it’s reasonable to begin the conversation with their oncologist about whether these drugs or related clinical trials may be appropriate,” Dr. Farrell says. Because pancreatic cancer often progresses quickly, he adds, exploring options early can matter. Individual eligibility depends on tumor genetics, prior treatment, and overall health.
Daraxonrasib is not a cure, and expectations should stay measured. “The drug works for a period of time, but the disease is quite crafty,” Dr. Farrell says. “It can find other pathways and continue to grow.” Over time, many tumors develop resistance, and not all patients respond in the first place. Side effects can include fatigue, nausea, and gastrointestinal symptoms.
Even with those limits, experts describe the results as a meaningful step forward for a disease with historically few options. If approved, doctors expect the drug to eventually move into earlier stages of treatment, including for patients whose cancer has not spread or who are candidates for surgery. “It will likely move into other settings over time,” Dr. Farrell says. “We’ll begin to see how it performs not just in advanced disease, but in patients earlier in the course of their illness.”
Researchers are also studying several other KRAS-targeted drugs, and improving early detection and prevention remains a long-term priority. “This is just the start,” Dr. Farrell says. “Now that we know this target can be successfully treated, it opens up the field for other drugs and new approaches.”